Explore lipid formulations studied for local RNA delivery in joints. Reported expression and therapeutic-response endpoints are described in their experimental context.
3 products currently listedResearch-use products only
FS01 is a squaramide-containing ionizable lipid investigated for local mRNA delivery to joints. In a head-to-head mouse intra-articular screen, FS01 lipid nanoparticles produced higher luciferase expression than formulations containing Lipid 5, SM-102 or LP01 under the tested conditions. FS01 was subsequently used to deliver IL-1Ra mRNA and a C-terminal truncated ANGPTL3 mRNA (ANL3), individually or in combination. The combined formulation was evaluated in mouse rheumatoid arthritis and osteoarthritis models for suppression of inflammation and preservation of cartilage. These findings support research into intra-articular mRNA delivery; the therapeutic results concern the complete mRNA-loaded formulation.
K9 is a novel ionizable lipid designed by the multi-objective AI model MOLEA. Its core function is to enable tissue-selective mRNA delivery. When formulated into Lipid Nanoparticles (LNPs), K9 can preferentially deliver mRNA efficiently to articular chondrocytes while significantly reducing delivery to hepatocytes. This facilitates targeted drug delivery for conditions like osteoarthritis and lowers the risk of off-target effects in the liver. In vitro experiments confirm that K9-LNPs promote endosomal escape and efficient expression of mRNA in chondrocytes. Its targeted delivery efficiency is further enhanced by optimizing the LNP formulation (e.g., lipid composition ratios) using a Design of Experiment (DoE) approach. In vivo studies show that after intra-articular injection, K9-LNPs exhibit high biodistribution and gene expression in the knee joint, with limited distribution in major organs like the liver. Therefore, K9 represents an advanced, rationally designed LNP component for achieving joint tissue-specific therapy, providing a key tool for developing targeted mRNA therapeutics.
